Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia
Closed
Phase 3
This trial is comparing venetoclax and azacitidine with azacitidine for acute myeloid leukaemia (AML). In this trial, the team are looking at having azacitidine as a tablet.
It is for people who have had chemotherapy and their leukaemia went away completely. This is called remission. It means there are no leukaemia cells in your blood or
Recruitment start: 6 October 2020
Recruitment end: 10 March 2023
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Richard Dillon
AbbVie
Last reviewed: 01 Dec 2023
CRUK internal database number: 16801